Meeder Asset Management Inc. Acquires Shares of 2,972 Janux Therapeutics, Inc. (NASDAQ:JANX)

Meeder Asset Management Inc. bought a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 2,972 shares of the company’s stock, valued at approximately $159,000.

A number of other institutional investors have also recently made changes to their positions in JANX. Charles Schwab Investment Management Inc. raised its stake in Janux Therapeutics by 202.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 234,191 shares of the company’s stock valued at $10,639,000 after acquiring an additional 156,675 shares during the period. Lester Murray Antman dba SimplyRich raised its position in shares of Janux Therapeutics by 205.3% in the fourth quarter. Lester Murray Antman dba SimplyRich now owns 24,315 shares of the company’s stock valued at $1,301,000 after purchasing an additional 16,351 shares during the period. Geode Capital Management LLC lifted its stake in shares of Janux Therapeutics by 6.2% during the 3rd quarter. Geode Capital Management LLC now owns 662,594 shares of the company’s stock valued at $30,107,000 after buying an additional 38,490 shares in the last quarter. Neo Ivy Capital Management bought a new position in Janux Therapeutics in the 3rd quarter worth approximately $940,000. Finally, abrdn plc purchased a new position in Janux Therapeutics in the 4th quarter valued at approximately $3,430,000. Hedge funds and other institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

Shares of Janux Therapeutics stock opened at $27.00 on Tuesday. The company has a 50 day simple moving average of $35.33 and a two-hundred day simple moving average of $45.87. The firm has a market cap of $1.60 billion, a PE ratio of -23.08 and a beta of 3.23. Janux Therapeutics, Inc. has a 1 year low of $26.40 and a 1 year high of $71.71.

Janux Therapeutics (NASDAQ:JANX) last announced its earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.49) by $0.13. Janux Therapeutics had a negative net margin of 463.91% and a negative return on equity of 10.47%. As a group, research analysts anticipate that Janux Therapeutics, Inc. will post -1.38 earnings per share for the current year.

Insider Transactions at Janux Therapeutics

In other news, insider Andrew Hollman Meyer sold 13,334 shares of the company’s stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $54.88, for a total value of $731,769.92. Following the completion of the sale, the insider now owns 82,139 shares of the company’s stock, valued at approximately $4,507,788.32. This represents a 13.97 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Ra Capital Management, L.P. bought 341,742 shares of the firm’s stock in a transaction that occurred on Wednesday, March 5th. The stock was acquired at an average price of $30.64 per share, for a total transaction of $10,470,974.88. Following the transaction, the director now owns 9,658,988 shares in the company, valued at $295,951,392.32. This trade represents a 3.67 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last three months, insiders sold 25,002 shares of company stock worth $1,279,953. 29.40% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

JANX has been the subject of a number of analyst reports. William Blair reaffirmed an “outperform” rating on shares of Janux Therapeutics in a report on Friday, January 10th. HC Wainwright restated a “buy” rating and issued a $70.00 target price on shares of Janux Therapeutics in a research note on Monday, March 3rd. Cantor Fitzgerald reiterated an “overweight” rating and set a $200.00 price target on shares of Janux Therapeutics in a research report on Wednesday, December 11th. Stifel Nicolaus raised their price objective on shares of Janux Therapeutics from $70.00 to $115.00 and gave the company a “buy” rating in a research report on Tuesday, December 3rd. Finally, Wedbush reaffirmed an “outperform” rating and set a $76.00 target price (up previously from $75.00) on shares of Janux Therapeutics in a report on Friday, February 28th. One research analyst has rated the stock with a hold rating, nine have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat, Janux Therapeutics has a consensus rating of “Buy” and an average price target of $92.44.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.